Peapod Lane Capital LLC Invests $836,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Peapod Lane Capital LLC purchased a new stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 108,853 shares of the company's stock, valued at approximately $836,000. Peapod Lane Capital LLC owned about 0.30% of iTeos Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of ITOS. State Street Corp grew its position in shares of iTeos Therapeutics by 21.9% during the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company's stock worth $12,000,000 after buying an additional 211,452 shares during the period. Geode Capital Management LLC grew its stake in iTeos Therapeutics by 3.2% in the third quarter. Geode Capital Management LLC now owns 640,350 shares of the company's stock valued at $6,540,000 after acquiring an additional 20,092 shares during the period. JPMorgan Chase & Co. increased its stake in iTeos Therapeutics by 1.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company's stock worth $4,771,000 after purchasing an additional 5,368 shares in the last quarter. Algert Global LLC raised its holdings in shares of iTeos Therapeutics by 92.0% during the third quarter. Algert Global LLC now owns 256,139 shares of the company's stock worth $2,615,000 after acquiring an additional 122,730 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of iTeos Therapeutics by 3.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 222,135 shares of the company's stock valued at $2,268,000 after purchasing an additional 8,397 shares in the last quarter. 97.16% of the stock is currently owned by institutional investors.

iTeos Therapeutics Stock Performance

ITOS traded up $0.13 during trading on Monday, reaching $7.40. 167,573 shares of the stock were exchanged, compared to its average volume of 250,342. The stock's 50 day moving average price is $7.66 and its two-hundred day moving average price is $10.27. iTeos Therapeutics, Inc. has a twelve month low of $7.06 and a twelve month high of $18.75. The stock has a market cap of $270.32 million, a P/E ratio of -2.35 and a beta of 1.38.

Analyst Ratings Changes

A number of research firms have recently issued reports on ITOS. Wells Fargo & Company lowered their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an "overweight" rating on the stock in a report on Thursday, December 19th. HC Wainwright restated a "buy" rating and set a $21.00 price objective on shares of iTeos Therapeutics in a research note on Thursday, January 16th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $25.00 target price on shares of iTeos Therapeutics in a research report on Friday, January 10th.

Insider Transactions at iTeos Therapeutics

In other iTeos Therapeutics news, CFO Matthew Gall purchased 5,000 shares of the company's stock in a transaction that occurred on Tuesday, November 19th. The shares were acquired at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the purchase, the chief financial officer now owns 65,429 shares in the company, valued at approximately $505,766.17. The trade was a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 12.50% of the stock is owned by company insiders.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.